Clinical trials: Acquired Ptosis
Blepharoptosis
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.
- Trial name
- NCT01848041
- Testing
- RVL-1201
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Blepharoptosis
A Study in Chinese Patients With Acquired Blepharoptosis
This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis.
- Trial name
- NCT06683651
- Testing
- STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800
- Where
- 23 sites in China
- Volunteers
- 180 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Acquired Blepharophimosis
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
- Trial name
- NCT06514612
- Testing
- STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
- Where
- 36 sites in Czechia, France and 7 more
- Volunteers
- 234 people
- Sponsor
- Santen SAS
Acquired Ptosis
Upneeq vs. Lumify Ptosis
This study aims to compare the short-term effect of oxymetazoline 0.1% (Upneeq) versus brimonidine 0.025% (Lumify) on upper-eyelid position in adults with acquired ptosis.
- Trial name
- NCT07390578
- Testing
- Oxymetazoline 0.1% (Upneeq), Brimonidine 0.025% (Lumify)
- Volunteers
- 50 people
- Sponsor
- Duke University
Acquired Blepharoptosis
LEV102 Topical Gel in Acquired Blepharoptosis
Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.
- Trial name
- NCT05715346
- Testing
- LEV102 1.0%, LEV102 2.0%, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Levation Pharma, Ltd.
Blepharoptosis
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
- Trial name
- NCT03536949
- Testing
- RVL-1201, Vehicle ophthalmic solution
- Where
- 35 sites in United States
- Volunteers
- 234 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Blepharoptosis, Synkinesis
Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle.
- Conditions
- Blepharoptosis, Synkinesis, Hyperkinesis, Facial Paralysis
- Trial name
- NCT05945615
- Testing
- Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Acquired Blepharoptosis
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an…
- Trial name
- NCT02436759
- Testing
- RVL-1201
- Where
- 14 sites in United States
- Volunteers
- 140 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Blepharoptosis
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
- Trial name
- NCT03565887
- Testing
- RVL-1201, Vehicle ophthalmic solution
- Where
- 36 sites in United States
- Volunteers
- 164 people
- Sponsor
- RVL Pharmaceuticals, Inc.